6869 N Stock Overview
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Sysmex Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥921.96 |
| 52 Week High | JP¥1,247.91 |
| 52 Week Low | JP¥921.96 |
| Beta | 0.60 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -63.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6869 N | MX Medical Equipment | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how 6869 N performed against the MX Medical Equipment industry.
Return vs Market: Insufficient data to determine how 6869 N performed against the MX Market.
Price Volatility
| 6869 N volatility | |
|---|---|
| 6869 N Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: 6869 N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 6869 N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 9,500 | Hisashi Ietsugu | www.sysmex.co.jp |
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.
Sysmex Corporation Fundamentals Summary
| 6869 N fundamental statistics | |
|---|---|
| Market cap | Mex$185.16b |
| Earnings (TTM) | Mex$5.42b |
| Revenue (TTM) | Mex$49.09b |
34.1x
P/E Ratio3.8x
P/S RatioIs 6869 N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6869 N income statement (TTM) | |
|---|---|
| Revenue | JP¥419.82b |
| Cost of Revenue | JP¥196.29b |
| Gross Profit | JP¥223.53b |
| Other Expenses | JP¥177.16b |
| Earnings | JP¥46.38b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Nov 08, 2023
| Earnings per share (EPS) | 221.57 |
| Gross Margin | 53.24% |
| Net Profit Margin | 11.05% |
| Debt/Equity Ratio | 0% |
How did 6869 N perform over the long term?
See historical performance and comparison